Operation Warp Speed, the federal government’s multi-agency push to develop a COVID-19 vaccine, is promising to provide 300 million doses by January 2021. That means funding for several of the top candidates. Moderna, one of the leaders of the pack, is already in Phase III trials after creating its first vaccine in a record-breaking 42 days.

The New York Times vaccine tracker lists more than 165 vaccines, with 28 being tested in humans. Those being developed by Pfizer, the University of Oxford in conjunction with AstraZeneca, Chinese companies Sinopharm and Sinovac, and the Murdoch Children’s Research Institute in Australia are all in Phase III trials. (Thomas Jefferson University, with a vaccine designed by Matthias Schnell, announced a partnership in May with Bharat Biotech, an Indian biotech company; they expect to reach clinical trials by December.)

MORE…

Canan Schuman, PharmD/PhD
Author: Canan Schuman, PharmD/PhD

Canan Schumann is Chief Editor for Axxiem and for Axxiem's blog "BiotechOntheWeb". When not writing for Axxiem, Canan works as a Clinical Research Scientist II at the Research and Development Department at Molecular Testing Labs, developing endpoint assays for the detection of infectious disease and cancer. Canan currently resides in Portland, Oregon, where he received his Honors Bachelor of Science (HBS), Doctor of Pharmacy (PharmD.), and his Doctor of Philosophy (Ph.D.) in Biopharmaceutics at Oregon State University.